'The Top Line': Humira's patent cliff and 2023's other big patent expirations, plus this week's headlines

For a long time, AbbVie’s Humira was the world’s top-selling drug. But the bestseller will finally face biosimilar competition. Plus, this year is also chock-full of other big-name, blockbuster drugs headed for the patent cliff. In this episode, we discuss 2023's patent story. 

Plus, we cover how Johnson & Johnson is looking to end its talc litigation with a sweeping settlement and more of this week's top headlines. 

 

To learn more about the topics in this episode: 

"The Top Line" is produced by senior podcast producer Teresa Carey and managing editor Querida Anderson. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.

To Listen to More Episodes from The Top Line